Systemic therapy in renal cell carcinoma: advancing paradigms.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Oncology

• Publication date

  2012-03-16

• Fields of study

  Medicine

• Identifiers
  PMID 22545314
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma

  2011cited by this paper
• Phase I Dose-Escalation Study and Biomarker Analysis of E7080 in Patients with Advanced Solid Tumors

  2011cited by this paper
• Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial.

  2011cited by this paper
• Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial

  2011cited by this paper
• A phase II study of dovitinib (TKI258), an FGFR- and VEGFR-inhibitor, in patients with advanced or metastatic renal cell cancer (mRCC).

  2011cited by this paper
• Phase 1 dose‐escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma

  2011cited by this paper
• AMG 386 in combination with sorafenib in patients (pts) with metastatic renal cell cancer (mRCC): A randomized, double-blind, placebo-controlled, phase II study.

  2011cited by this paper
• A Phase I study of recombinant human interleukin-21 (rIL-21) in combination with sunitinib in patients with metastatic renal cell carcinoma (RCC)

  2011cited by this paper
• NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy.

  2011cited by this paper
• First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.

  2011cited by this paper
• A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma

  2011cited by this paper
• Cancer statistics, 2011

  2011cited by this paper
• A phase I trial of combined tivozanib (AV-951) and temsirolimus therapy in patients (pts) with renal cell carcinoma (RCC).

  2011cited by this paper
• Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

  2011cited by this paper
• Monitoring T-cell responses in a phase II study of AGS-003, an autologous dendritic cell-based therapy in patients with newly diagnosed advanced stage renal cell carcinoma in combination with sunitinib.

  2011cited by this paper
• Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

  2011cited by this paper
• A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors

  2011cited by this paper
• TORAVA trial: Lessons from this trial in the two control arms, sunitinib and bevacizumab in combination with interferon.

  2011cited by this paper
• The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy.

  2011cited by this paper
• A phase I study to evaluate safety and antitumor activity of biweekly BMS-936558 (Anti-PD-1, MDX-1106/ONO-4538) in patients with RCC and other advanced refractory malignancies.

  2011cited by this paper
• Overexpression of fibroblast growth factor receptors FGFR1 and FGFR2 in renal cell carcinoma

  2011cited by this paper
• Phase I/II Trial of Sunitinib Plus Gefitinib in Patients With Metastatic Renal Cell Carcinoma

  2010cited by this paper
• Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.

  2010cited by this paper
• A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma

  2010cited by this paper
• Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial

  2010cited by this paper
• Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma.

  2010cited by this paper
• Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.

  2010cited by this paper
• Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206.

  2010cited by this paper
• Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma.

  2010cited by this paper
• Feasibility and efficacy of neoadjuvant sunitinib before nephron‐sparing surgery

  2010cited by this paper
• Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma.

  2010cited by this paper
• Results of a randomized phase II study investigating multipeptide vaccination with IMA901 in advanced renal cell carcinoma (RCC).

  2010cited by this paper
• Activity of tivozanib (AV-951) in patients with renal cell carcinoma (RCC): Subgroup analysis from a phase II randomized discontinuation trial (RDT).

  2010cited by this paper
• A phase II study testing the safety and activity of AGS-003 as an immunotherapeutic in subjects with newly diagnosed advanced stage renal cell carcinoma (RCC) in combination with sunitinib.

  2010cited by this paper
• Immunomonitoring of a phase I/II study of AGS-003, a dendritic cell immunotherapeutic, as first-line treatment for metastatic renal cell carcinoma.

  2010cited by this paper
• Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours.

  2010cited by this paper
• Randomized trial of adjuvant thalidomide versus observation in patients with completely resected high-risk renal cell carcinoma.

  2009cited by this paper
• Phase I Study of the Angiogenesis Inhibitor BIBF 1120 in Patients with Advanced Solid Tumors

  2009cited by this paper
• Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors.

  2009cited by this paper
• Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma.

  2009cited by this paper
• Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.

  2009cited by this paper
• A phase II study of two dosing regimens of GSK 1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in patients (pts) with papillary renal carcinoma (PRC).

  2009cited by this paper
• Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317.

  2009cited by this paper
• Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma.

  2009cited by this paper
• Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

  2009cited by this paper
• CD4+ regulatory T cells require CTLA-4 for the maintenance of systemic tolerance

  2009cited by this paper
• Phase 1 Study of Aflibercept Administered Subcutaneously to Patients with Advanced Solid Tumors

  2009cited by this paper
• Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low‐dose interferon alfa in patients with advanced renal cell carcinoma

  2009cited by this paper
• 49LBA Final results of a Phase II randomised study of cediranib (RECENTIN™) in patients with advanced renal cell carcinoma (RCC)

  2009cited by this paper
• Multi-Kinase Inhibitor E7080 Suppresses Lymph Node and Lung Metastases of Human Mammary Breast Tumor MDA-MB-231 via Inhibition of Vascular Endothelial Growth Factor-Receptor (VEGF-R) 2 and VEGF-R3 Kinase

  2008cited by this paper
• Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.

  2008cited by this paper
• Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial.

  2008cited by this paper
• Activity of cediranib (AZD2171) in patients (pts) with previously untreated metastatic renal cell cancer (RCC). A phase II trial of the PMH Consortium

  2008cited by this paper
• BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.

  2008cited by this paper
• Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.

  2008cited by this paper
• A phase I study to evaluate safety, immunogenicity and anti-tumor activity of the multi-peptide vaccine IMA901 in renal cell carcinoma patients (RCC)

  2007cited by this paper
• Sorafenib in advanced clear-cell renal-cell carcinoma.

  2007cited by this paper
• Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

  2007cited by this paper
• Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

  2007cited by this paper
• Correlation of T-cell response, clinical activity and regulatory T-cell levels in renal cell carcinoma patients treated with IMA901, a novel multi-peptide vaccine

  2007cited by this paper
• Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma.

  2007cited by this paper
• PD-1 Is Expressed by Tumor-Infiltrating Immune Cells and Is Associated with Poor Outcome for Patients with Renal Cell Carcinoma

  2007cited by this paper
• Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and Hypophysitis

  2007cited by this paper
• Significance of B7-H1 overexpression in kidney cancer.

  2006cited by this paper
• KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties.

  2006cited by this paper
• Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up.

  2006cited by this paper
• Adjuvant subcutaneous interleukin-2 in patients with resected renal cell carcinoma: a pilot study.

  2006cited by this paper
• In vivo Target Modulation and Biological Activity of CHIR-258, a Multitargeted Growth Factor Receptor Kinase Inhibitor, in Colon Cancer Models

  2005cited by this paper
• Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results.

  2005cited by this paper
• Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target.

  2004cited by this paper
• VEGF-Trap: A VEGF blocker with potent antitumor effects

  2002cited by this paper
• Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy

  2002cited by this paper
• Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.

  2001cited by this paper
• Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial.

  2001cited by this paper
• Familial clear cell renal cell carcinoma (FCRC): clinical features and mutation analysis of the VHL,MET, and CUL2candidate genes

  2000cited by this paper
• Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development.

  1999cited by this paper
• Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

  1999cited by this paper
• Overexpression of c-met proto-oncogene associated with chromophilic renal cell carcinoma with papillary growth

  1998cited by this paper
• Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report.

  1994cited by this paper
• Epidermal growth factor receptor gene expression in normal human kidney and renal cell carcinoma.

  1989cited by this paper

• NCF1/2/4 Are Prognostic Biomarkers Related to the Immune Infiltration of Kidney Renal Clear Cell Carcinoma

  2021cites this paper
• Expression and clinical significance of NUF2 in kidney renal clear cell carcinoma

  2021cites this paper
• Local and Regional Recurrences of Clinically Localized Renal Cell Carcinoma after Nephrectomy: A 15 Year Institutional Experience with Prognostic Features and Oncologic Outcomes.

  2021cites this paper
• lncRNA MSC‐AS1 activates Wnt/β‐catenin signaling pathway to modulate cell proliferation and migration in kidney renal clear cell carcinoma via miR‐3924/WNT5A

  2020cites this paper
• MicroRNA-218 inhibits tumor angiogenesis of human renal cell carcinoma by targeting GAB2

  2020cites this paper
• LHPP Inhibits the Proliferation and Metastasis of Renal Cell Carcinoma

  2020cites this paper
• LncRNA NONHSAT113026 represses renal cell carcinoma tumorigenesis through interacting with NF-κB/p50 and SLUG.

  2019cites this paper
• LncRNA MALAT1 modified progression of clear cell kidney carcinoma (KIRC) by regulation of miR‐194‐5p/ACVR2B signaling

  2018cites this paper
• Evaluation of Therapeutic Potential of Phenoxodiol, a Novel Isoflavone Analog, in Renal Cancer Cells

  2018cites this paper
• Delanzomib Interacts with Ritonavir Synergistically to Cause Endoplasmic Reticulum Stress in Renal Cancer Cells

  2018cites this paper
• Renal fossa recurrence after nephrectomy for renal cell carcinoma: prognostic features and oncological outcomes

  2017cites this paper
• Etiologies and management of cutaneous flushing: Malignant causes.

  2017cites this paper
• Etiologies and management of cutaneous flushing: Nonmalignant causes.

  2017cites this paper
• Therapeutic Antibodies in Cancer Therapy.

  2016cites this paper
• Therapeutic challenges in renal cell carcinoma.

  2015cites this paper
• Combination treatment of renal cell carcinoma with belinostat and 5-fluorouracil: a role for oxidative stress induced DNA damage and HSP90 regulated thymidine synthase.

  2015cites this paper
• Signalling pathways involved in antitumoral effects of VIP in human renal cell carcinoma A498 cells: VIP induction of p53 expression.

  2014cites this paper
• Acquired Hypothyroidism as a Predictive Marker of Outcome in Patients With Metastatic Renal Cell Carcinoma Treated With Tyrosine Kinase Inhibitors: A Literature-Based Meta-Analysis.

  2014cites this paper
• Red face revisited: Flushing.

  2014cites this paper
• Entfernung des Primärtumors bei hämatogen metastasierter Tumorerkrankung

  2014cites this paper
• Experience with Pazopanib in the Treatment of Metastatic Renal Cell Carcinoma: A Monocentric Experience

  2014cites this paper
• Solitary renal fossa recurrence of renal cell carcinoma after nephrectomy.

  2014cites this paper
• Practice challenges afecting optimal care as identifed by US medical oncologists who treat renal cell carcinomas

  2014cites this paper
• Practice challenges affecting optimal care as identifed by US medical oncologists who treat renal cell carcinomas.

  2014cites this paper
• Making sense of dietary calcium and urinary stone disease

  2014cites this paper
• VEGF/VEGFR2 and PDGF-B/PDGFR-β expression in non-metastatic renal cell carcinoma: a retrospective study in 1,091 consecutive patients.

  2014cites this paper
• Clinico-pathological prognostic factors of renal cell carcinoma: A 15-year review from a single center in Greece

  2014cites this paper
• [Removal of the primary tumor in hematogenous metastatic tumor disease: reasons against].

  2014cites this paper
• Entfernung des Primärtumors bei hämatogen metastasierter Tumorerkrankung

  2014cites this paper
• Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study.

  2014cites this paper
• Management of metastatic renal cell carcinoma patients with poor-risk features: current status and future perspectives

  2013cites this paper
• Brachytherapy for isolated tongue metastasis of renal clear cell carcinoma.

  2013cites this paper
• Molecular Signatures in Urologic Tumors

  2013cites this paper
• Clinical opportunities and challenges in targeting tumour dormancy

  2013cites this paper
• Immunotherapy in renal cell cancer: the more the merrier?

  2013cites this paper
• Identification of Pre- and Post-Treatment Markers, Clinical, and Laboratory Parameters Associated with Outcome in Renal Cancer Patients Treated with MVA-5T4

  2013cites this paper
• OM-RCA-01, a novel humanized monoclonal antibody targeting fibroblast growth factor receptor 1, in renal cell carcinoma model

  2013cites this paper
• New Systemic Treatment Approaches for Metastatic Renal Cell Carcinoma

  2013cites this paper
• Adherence to targeted oral anticancer medications.

  2013cites this paper
• Curiethérapie pour une métastase linguale isolée d’un cancer du rein à cellules claires

  2013cites this paper
• Regulation of blood-testis barrier (BTB) dynamics during spermatogenesis via the "Yin" and "Yang" effects of mammalian target of rapamycin complex 1 (mTORC1) and mTORC2.

  2013cites this paper
• FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer

  2013cites this paper
• The effect of sorafenib treatment on the diabetic status of patients with renal cell or hepatocellular carcinoma.

  2012cites this paper
• Expression of EZH2 in renal cell carcinoma as a novel prognostic marker

  2012cites this paper
• Dual PI3K/mTOR inhibitor NVP-BEZ235 suppresses hypoxia-inducible factor (HIF)-1α expression by blocking protein translation and increases cell death under hypoxia

  2012cites this paper
• Sequential therapy in metastatic clear cell renal carcinoma: TKI–TKI vs TKI–mTOR

  2012cites this paper
• Cancer of the Kidney

  2011cites this paper